PharmaCyte Ventures Into Cannabis Research
Pancreatic cancer is inoperable, and it’s taken some of our
best including Patrick Swayze and Steve Jobs. A mere 25% survive the first year
alone. Apparently, cannabis may help that change. PharmaC
[dropcap class=”kp-dropcap”]P[/dropcap]ancreatic cancer is inoperable, and it’s taken some of our best including Patrick Swayze and Steve Jobs. A mere 25 percent survive the first year alone; however, cannabis may help change that fact. PharmaCyte Biotech (PMCB) released a press release introducing the world to Cell-in-a-Box®, its signature patented encapsulation technology. PharmaCyte plans on exploiting the anti-cancer applications of cannabinoids.
PharmaCyte researches believe cannabinoids are essential to completing the treatment. Recently PharmaCyte researchers outlined their objective for potential shareholders. “PharmaCyte Biotech is also developing treatments for cancer based upon the encapsulation of chemical constituents of the Cannabis plant. It is examining ways to exploit the benefits of the Cell-in-a-Box® technology in optimizing the anti-cancer effectiveness of Cannabis, while at the same time, minimizing or outright eliminating the debilitating side effects often associated with cancer treatments.”
Marie Powers of BioWorld reported, “Considering its relatively inconspicuous presence in the body, the pancreas can wreak havoc on human health through two major diseases: Diabetes and pancreatic cancer. Both can be deadly–the former from the condition itself or from long-term complications and the latter from advanced disease that may be msymptomatic for only months or even weeks. Neither has a cure… PharmaCyte Biotech Inc. aspires to change that bleak prognosis with a technology that can attack both culprits. “
According to their press release, PharmaCyte has acquired exclusive worldwide rights to use Melligen cells. Melligen cells are genetically engineered liver cells that produce insulin when exposed to higher concentration of glucose levels. PharmaCyte says the Melligen cells are genetically engineered to produce, store and secrete insulin. The “cocoons” keep the cells from being attacked by the patient’s immune system. PharmaCyte believes the addition of cannabinoids will help in several different
ways.
PharmaCyte’s clinical trials are currently studying mice and will migrate to pigs— an animal that’s biologically and anatomically close to humans. Through cannabinoid use, PharmaCyte hopes to pioneer stem cell treatment for the reversal of diabetes and for the treatment of inoperable cancers.
